Using an artificial intelligence (AI)-driven algorithm, we retrospectively assessed the value of intratumoral CD8 topology together with PD-L1 expression as a composite biomarker of response to immunotherapy in patients with advanced melanoma in the phase 3 CheckMate 067 clinical trial (NCT01844505)
Lee et al.
Get In Touch
PathAI Media
Company Contact
Liz Storti
Chief People Officer
Media Contact
Daniel Donato
LifeSci Communications
516-474-0554